There has been a major revision of the ICH guidance regarding the use of women of child bearing potential in clinical trials.
“In all ICH regions, inclusion of women of childbearing potential in clinical trials may be acceptable without non-clinical reproductive/development toxicology studies in certain circumstances”
The current ICH M3 states:
In the EU, assessment of embryo-fetal development should be completed prior to Phase I trials in women of childbearing potential.
In the US women of childbearing potential may be included in early, carefully monitored studies without reproduction toxicity studies provided appropriate precautions are taken to minimise risk.
The revise M3 states:
in all ICH regions women of child bearing potential can be included in clinical trials without non-clinical development toxicity studies (e.g., embryo-fetal studies) in certain circumstances.
In all ICH regions, women of child bearing potential can be included in repeated-dose Phase 1 and 2 trials prior to the conduct of the female fertility study since an evaluation of the female reproductive organs is performed in the repeated dose toxicity studies.
Two forms of contraception are required, one barrier and one hormonal.
Please note that in the EU this is NOT default position, it only applied in certain cases and includes restriction on numbers and duration.
This is important for a regulatory strategy and clinical development strategy front as it can have a huge impact on trial designs, and more importantly recruitment rates in early development. it also reduces the early stage burden in the development of female specific therapies.
If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com
Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch
For Assistance with Regulatory Planning and Exicution of Clinical Trials Click Here
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!
Fill Out the Short Form Below… |
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Pingback: ICH M3 (R2) Non-clinical Safety Studies Guidance updated by EMEA | Drug Development Consultant and Regulatory Consultant